The first dual-action GIP/GLP-1 receptor agonist. Mounjaro for diabetes, Zepbound for weight loss — and weight loss numbers that have rewritten expectations for what a drug can do. Here is what the data actually supports.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. Unlike semaglutide, which only targets the GLP-1 receptor, tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously.
Developed by Eli Lilly, it was approved as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. It is administered as a once-weekly subcutaneous injection, like semaglutide.
The dual-receptor approach is what makes tirzepatide genuinely different — not just "another GLP-1." GIP and GLP-1 are both incretin hormones released by your gut after eating, but they work through different pathways. Hitting both receptors appears to produce more weight loss and comparable or better glucose control than GLP-1 alone.
Think of GLP-1 and GIP as two different appetite and metabolism levers. Semaglutide pulls one lever. Tirzepatide pulls both. GLP-1 primarily works through appetite suppression and slowed gastric emptying. GIP adds effects on fat tissue metabolism, nutrient sensing, and potentially improved insulin sensitivity through a different cellular pathway.
The result in trials: more weight loss, and the additional GIP activity may help explain why some patients tolerate tirzepatide differently than pure GLP-1 drugs. But "dual mechanism" does not automatically mean "twice as good" — biology is not that simple.
Tirzepatide hit the market in the middle of the GLP-1 media frenzy. The hype machine was already warmed up from semaglutide, and the bigger weight loss numbers gave it even more fuel.
The SURMOUNT trial program is to tirzepatide what the STEP program was to semaglutide — large, rigorous, randomized controlled trials that established the clinical evidence base.
You cannot reliably compare SURMOUNT numbers to STEP numbers.
The "tirzepatide produces 50% more weight loss than semaglutide" claim comes from comparing across different trials with different patient populations, different durations, and different lifestyle intervention protocols. This is a well-known statistical error called indirect comparison.
As of mid-2026, no large, published head-to-head randomized trial directly comparing semaglutide 2.4mg vs tirzepatide 15mg exists. Until that data arrives, claiming one is definitively "better" than the other is getting ahead of the science. The SURPASS-2 trial compared tirzepatide to semaglutide 1mg (the diabetes dose, not the weight loss dose) — this is not a fair weight-loss comparison.
One of the most persistent claims about tirzepatide is that it has "fewer side effects than Ozempic." The data tells a more nuanced story:
Dose-dependent. Lower end at 5mg, higher at 15mg. Comparable to semaglutide at equivalent titration stages.
Similar range across dose levels. Tends to be mild to moderate and improves over time.
Lower than semaglutide's 24% in STEP 1, but different trial designs make direct comparison imprecise.
About 4-7% of SURMOUNT-1 participants discontinued due to adverse events — in the same range as semaglutide trials. The GI profile is similar, not dramatically better. Individual tolerance varies enormously — some people tolerate tirzepatide well who struggled with semaglutide, and vice versa.
The SURPASS trial program established tirzepatide for type 2 diabetes management:
This is a critical gap in the tirzepatide evidence base. Semaglutide has the SELECT trial showing a 20% reduction in major cardiovascular events. Tirzepatide does not yet have an equivalent published outcome trial.
The SURPASS-CVOT trial is underway and will provide dedicated cardiovascular outcomes data. Until results are published, the cardiovascular benefit of tirzepatide is inferred from metabolic improvements (weight loss, glucose control, lipid changes) — not proven by a dedicated outcomes trial.
This does not mean tirzepatide is cardiovascularly unsafe — it means the evidence is not yet at the same level as semaglutide. For patients whose primary concern is cardiovascular risk reduction, semaglutide currently has stronger evidence.
Early body composition data from SURMOUNT trials suggests that tirzepatide may preserve a higher proportion of lean mass compared to weight lost — meaning a greater fraction of the weight loss is fat, not muscle.
This is biologically plausible: GIP receptors are expressed on adipose tissue and may preferentially mobilize fat stores. However, dedicated body composition sub-studies with DEXA confirmation are still being analyzed. As with semaglutide, resistance training remains the most reliable way to preserve muscle on any rapid weight loss program.
The weight loss numbers from SURMOUNT-1 are genuinely unprecedented: 22.5% average body weight reduction at the highest dose, with over a third of participants exceeding 25%. The dual GIP/GLP-1 mechanism is a real pharmacological innovation, not marketing spin.
But "Ozempic killer" is a headline, not science. There is no published head-to-head trial at full weight-loss doses. GI side effects are similar, not dramatically better. Cardiovascular outcomes data is still being collected. And the 22.5% average means some people lost more and some lost significantly less — averages are not guarantees.
Tirzepatide is a genuinely impressive drug with a novel mechanism. For some people, it will work better than semaglutide. For others, the reverse will be true. The only way to know which camp you fall into is to track your own response — your weight, your side effects, your body composition, your bloodwork. That is exactly what Dosi is built for.
Tirzepatide uses a monthly titration schedule — each dose is maintained for 4 weeks before the next increase. The schedule is more gradual than semaglutide, with six dose levels rather than five.
The tracking priorities for tirzepatide are similar to semaglutide — with a few additions that matter if you are switching between the two or comparing your response.
Weekly, same conditions. The trend over weeks matters more than any single weigh-in.
Monthly DEXA or bioimpedance. Especially important given the potential lean-mass preservation advantage — track it, don't assume it.
Daily during titration. Log severity of nausea, diarrhea, vomiting, constipation. Compare across dose levels to find your tolerability ceiling.
Brief daily log. Note any changes from baseline, especially during dose increases.
Fasting glucose weekly if you have a meter. HbA1c every 3 months via lab work. Essential if you have T2D or prediabetes.
Log location each week. Rotate belly, thigh, arm. Track any site reactions or bruising.
Note reduced cravings, portion changes, food aversions. Many patients report specific taste and appetite shifts.
If you previously used semaglutide, log the same metrics consistently so you can compare your personal response across drugs.
Log doses, side effects, injection sites, and body composition. Your data will tell you how tirzepatide works for your body — not how it worked in a trial average.
Get Started Free →